- Trial phase
- Phase 1
- Time to market
- ZW191 is in Phase 1 with no registrational trial design announced. Assuming successful Phase 1 completion, a Phase 2/3 registrational trial would likely start in 2027, putting a potential FDA submission several years away, likely 2029 or later.
- Why 4/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ZW191 in the next ~12 months. The drug is in Phase 1 with no announced registrational trial start date. ZW191 is one of several pipeline assets at a multi-asset company that also has an approved drug (Ziihera), royalty streams, and a Roche partnership, so even a Phase 2 start would not be a single-asset binary event.
The next catalyst for ZW191 is likely updated Phase 1 data at a medical conference in 2027 or news of Phase 2/registrational trial initiation. Zymeworks reports Q4 2026 earnings in early 2027, which may include a pipeline update. The strong ESMO 2026 response rate (64.5%) supports advancement, but the drug remains early-stage with no hard binary catalyst on the calendar.
Price Chart
Executive Summary
ZW191 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRalpha), being developed by Zymeworks Inc. (NASDAQ: ZYME) primarily for platinum-resistant ovarian cancer. It is currently in Phase 1 clinical testing, with the first patient dosed in November 2024. The drug has shown promising early efficacy data: a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated patients at ESMO 2026, and a 61% response rate with median progression-free survival of 7.6 months at AACR 2026. The FDA granted Fast Track designation in March 2026. ZW191 faces competition from AbbVie's already-approved Elahere (mirvetuximab soravtansine) but differentiates via a novel topoisomerase I inhibitor payload and activity across all FRalpha expression levels. Zymeworks is a multi-asset company with an approved drug (Ziihera), royalty streams, and a Roche collaboration, so ZW191 is one of several value drivers rather than a single-asset binary.
How It Works
ZW191 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy that works like a guided missile. One part of the drug (the antibody) seeks out and binds to a protein called folate receptor alpha (FRalpha) that is found on the surface of many ovarian, endometrial and lung cancer cells. Once attached, the drug delivers a potent chemotherapy payload (a topoisomerase I inhibitor called ZD06519) directly inside the cancer cell, killing it while largely sparing healthy cells. The drug is designed with a high drug-to-antibody ratio, meaning each antibody carries multiple payload molecules for a stronger kill effect.
Trial Status
ZW191 is in an ongoing Phase 1 trial (first patient dosed November 2024) evaluating it in FRalpha-expressing advanced solid tumors including ovarian, endometrial, and non-small cell lung cancer. The dose-escalation portion was completed and presented at AACR 2026. A randomized dose-optimization portion was presented at ESMO Congress 2026, showing a 64.5% confirmed objective response rate at the 6.4 mg/kg dose in platinum-resistant ovarian cancer. The company has not yet announced a Phase 2 or registrational trial start date.
The Two-Sided Case
Upcoming Catalysts
- Updated Phase 1 data at a medical conference in 2027 (e.g., ASCO, ESMO, SGO)
- Announcement of Phase 2 or registrational trial design and initiation
- Potential partnership or licensing deal for ZW191 given Zymeworks' partnering-focused strategy
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zymeworks Inc. PRESS-RELEASE ZYME ·Originating report